Overview
sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C>1.8mmol/L) without endovascular therapy.
Description
sICASBLM aims to determine the effectiveness of conventional lipid management combined with PCSK9 inhibitors compared to conventional lipid management (atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg) in reducing the incidence of recurrent stroke in patients with moderate to severe symptomatic intracranial atherosclerotic stenosis (LDL-C>1.8mmol/L) without endovascular therapy.
Eligibility
Inclusion Criteria:
- Age ≥18 years
- Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment
- low density lipoprotein cholesterol > 70mg/dl (1.8mmol/L)
- Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained.
- Lipid-lowering indications of statins
- Signed an approved informed consents
Exclusion Criteria:
- Contraindications to statins
- There are contraindications to MRI examination or cannot accept MRI examination
- Stenosis caused by vasculitis, arterial dissection and moyamoya disease
- Patients with active bleeding or obvious bleeding tendency
- Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating
- Uncontrolled severe diabetes and hypertension
- Other conditions inappropriate for inclusion judged by investigators